Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: A prospective trial

Akimitsu Maeda, Hiroki Yoshida, Hirotaka Inoue, Masayuki Ejiri, Satoe Yamaguchi, Hideyuki Kushihara, Yoshihiro Yamamoto, Yosuke Ando, Yumiko Sato, Yuusuke Tashiro, Ayako Hasegawa, Yuko Takahara, Mika Mizutani, Isao Oze, Junichi Shimizu

研究成果: ジャーナルへの寄稿学術論文査読

1 被引用数 (Scopus)

抄録

Background: Olanzapine 10 mg is recommended for breakthrough chemotherapy-induced nausea and vomiting. However, there is a possibility that 5 mg can be expected to be sufficiently effective. We aimed to investigate the efficacy and safety of olanzapine 5 mg for breakthrough chemotherapy-induced nausea and vomiting. Methods: A single-arm prospective trial of olanzapine 5 mg every 24 h for 72 h was conducted to treat breakthrough chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy. The primary endpoint was total control (i.e., no emesis, no nausea, and no rescue medications) over 72 h. The secondary endpoints were early efficacy using the nausea scores at 30, 60, and 120 min after taking olanzapine from baseline and adverse events. Results: Among 84 potentially eligible patients, 19 patients who took olanzapine for breakthrough chemotherapy-induced nausea and vomiting were examined. The total control rate was 32% (95% CI: 13– 57%), 65% (95% CI: 38–89%), 65% (95% CI: 38–89%), and 29% (95% CI: 10–56%) during 2–24, 24–48, 48–72 h, and overall period, respectively. The nausea scale significantly reduced after 30 min (P=0.0078), and the scale had been reduced by 67% from the baseline after 60 min. The adverse event of somnolence of any grade was observed in 13 (68%) patients, 6 (32%) of whom had grade 2 and 1 (5%) grade 3 somnolence. Conclusions: Olanzapine 5 mg did not show the expected effect on the complete disappearance of breakthrough chemotherapy-induced nausea and vomiting within 24 h.

本文言語英語
ページ(範囲)2699-2708
ページ数10
ジャーナルAnnals of palliative medicine
10
3
DOI
出版ステータス出版済み - 2021

All Science Journal Classification (ASJC) codes

  • 高度および特殊看護
  • 麻酔学および疼痛医療

フィンガープリント

「Effects of 5-mg dose of olanzapine for breakthrough nausea and vomiting in patients receiving carboplatin-based chemotherapy: A prospective trial」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル